Physician profile
Jonathan Stringer
NPI 1275742884
$7,463.51
in general payments reported to CMS, 2019-2025
41 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $958 · 2021: $727 · 2022: $1,091 · 2023: $1,668 · 2024: $1,176 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,268 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,267.69 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $921.76 | 2019-2025 | Freestyle Libre, Freestyle Libre 3 |
| Novo Nordisk INC | $590.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.90 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $507.97 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $494.98 | 2023-2025 | Minimed 780g, Inceptiv, Intellis Adaptivestim |
| Amgen INC. | $411.80 | 2019-2025 | Repatha, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $403.90 | 2021-2025 | |
| Dexcom, INC. | $360.03 | 2019-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $310.28 | 2019-2023 | |
| Insulet Corporation | $268.87 | 2019-2023 | Omnipod |
| Tandem Diabetes Care, INC. | $259.36 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $228.01 | 2020-2025 | Isturisa |
| Merck Sharp & Dohme LLC | $219.70 | 2020-2023 | Steglatro, Steglujan |
| Radius Health, INC. | $218.88 | 2019-2025 | Tymlos |
| Abbvie INC. | $213.42 | 2022-2025 | Synthroid, Botox |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $161.29 | 2024-2025 | |
| Antares Pharma, INC. | $147.06 | 2019-2025 | Xyosted |
| Cequr Corporation | $126.02 | 2024-2025 | Cequr Simplicity |
| Corcept Therapeutics | $111.39 | 2024-2025 | Korlym |
| Beta Bionics, INC. | $93.24 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Xeris Pharmaceuticals, INC. | $84.09 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Ascendis Pharma Endocrinology INC | $79.13 | 2025 | Yorvipath, Skytrofa |
| Bayer Healthcare Pharmaceuticals INC. | $74.73 | 2022-2023 | |
| Kyowa Kirin, INC. | $65.97 | 2023-2024 | Crysvita |
| Halozyme INC | $63.33 | 2023 | |
| Horizon Therapeutics Plc | $61.73 | 2021 | |
| Ibsa Pharma INC. | $56.94 | 2020 | |
| Sequel Med Tech, LLC | $55.10 | 2025 | Twiist |
| Medtronic Minimed, INC. | $51.04 | 2019-2020 | |
| Amryt Pharma Holdings Ltd | $48.77 | 2023 | Mycapssa |
| Neurocrine Biosciences, INC. | $46.74 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $45.82 | 2020-2025 | Strensiq |
| Amarin Pharma, INC. | $38.85 | 2019 | |
| Acella Pharmaceuticals, LLC | $36.70 | 2025 | NP Thyroid 60 |
| Chiesi USA, INC. | $26.21 | 2024 | Mycapssa |
| Averitas Pharma INC. | $21.37 | 2024 | Qutenza |
| Amneal Pharmaceuticals LLC | $14.40 | 2024 | Unithroid |
| Ipsen Biopharmaceuticals, INC | $13.63 | 2019 | |
| Roche Diabetes Care, INC. | $11.20 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.35 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Stringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.